Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11253689 | 0.98 | KIF11 (0.58) | KIF11EPHX2PTGS1TGM2NPC1 | |
| Bicarbonate SCHEMBL2945476 | 0.93 | KIF11 (0.62) | KIF11EPHX2PTGS1TGM2NPC1 | |
| Nitric Acid SCHEMBL2856189 | 0.88 | KIF11 (0.53) | KIF11EPHX2PTGS1TGM2NPC1 | |
| SCHEMBL4099321 | 0.85 | KIF11 (0.53) | KIF11EPHX2PTGS1TGM2NPC1 | |
| Hydrochloric Acid SCHEMBL16701795 | 0.83 | KIF11 (0.51) | KIF11EPHX2PTGS1TGM2NPC1 | |
| SCHEMBL11057676 | 0.82 | KIF11 (0.63) | KIF11EPHX2PTGS1CA1CA2 | |
| SCHEMBL11058297 | 0.82 | EPHX2 (0.68) | KIF11EPHX2PTGS1TGM2NPC1 | |
| SCHEMBL27683562 | 0.82 | MAOB (0.60) | — | |
| SCHEMBL1996992 | 0.82 | F2 (0.50) | NPC1RAB9AMAPT | |
| SCHEMBL27446924 | 0.80 | EPHX2 (0.55) | KIF11EPHX2PTGS1TGM2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022099-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12371408-B2 | Aryl hydrocarbon receptor agonists and uses thereof | NEXYS THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12168646-B2 | Aryl hydrocarbon receptor agonists and uses thereof | NEXYS THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4472953-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | Nexys Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118891251-A | Aryl hydrocarbon receptor agonists and uses thereof | 奈可萨斯医药有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240279185-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2023150197-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| US-3976643-A | FROM AN ANILINE AND CYANAMIDE | WILLIAM H. RORER, INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | KIF11 2614/4885EPHX2 3608/4885PTGS1 245/4885 |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | PRKCI, PIK3CA, AKT1 | KIF11 2483/4885EPHX2 3562/4885PTGS1 1379/4885 |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | KIF11 2483/4885EPHX2 3562/4885PTGS1 1379/4885 |
| US-12371408-B2 | Aryl hydrocarbon receptor agonists and uses thereof | AHR, ARNT, NR1H2 | KIF11 4788/4885EPHX2 790/4885PTGS1 634/4885 |
| US-20260022099-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, NR1H4, CNR1 | KIF11 4791/4885EPHX2 725/4885PTGS1 923/4885 |
| US-20240279185-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, ARNT, NR1H2 | KIF11 4788/4885EPHX2 790/4885PTGS1 634/4885 |
| US-12168646-B2 | Aryl hydrocarbon receptor agonists and uses thereof | AHR, ARNT, NR1H2 | KIF11 4788/4885EPHX2 790/4885PTGS1 634/4885 |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, ARNT, NR1H2 | KIF11 4788/4885EPHX2 790/4885PTGS1 634/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | KIF11 2614/4885EPHX2 3608/4885PTGS1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.